Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
REDWOOD CITY, Calif., April 06, 2016 -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on April 1, 2016 the compensation committee of the company’s board of directors granted 3 new employees options to purchase an aggregate of 7,450 shares of the company’s common stock with a per share exercise price of $13.30, the closing trading price on the grant date, and 3,725 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, Veltassa® (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
